The Sympathetic Nervous System in Chronic Kidney Disease

[1]  P. Blankestijn,et al.  Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. , 2001, Journal of the American Society of Nephrology : JASN.

[2]  F. Mahfoud Renale Sympathikusdenervation bei arterieller Hypertonie – Pro , 2012, Deutsche Medizinische Wochenschrift.

[3]  I. Reid Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. , 1992, The American journal of physiology.

[4]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[5]  M. Bots,et al.  Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. , 2009, Journal of nephrology.

[6]  P. Blankestijn,et al.  Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. Zanzinger Role of nitric oxide in the neural control of cardiovascular function. , 1999, Cardiovascular research.

[8]  R. Bigazzi,et al.  Altered norepinephrine turnover in the brain of rats with chronic renal failure. , 1994, Journal of the American Society of Nephrology : JASN.

[9]  M. Koss,et al.  Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  M. Esler,et al.  Sympathetic activation in chronic renal failure. , 2009, Journal of the American Society of Nephrology : JASN.

[11]  C. Zoccali,et al.  Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  E. Schiffrin,et al.  Chronic Kidney Disease: Effects on the Cardiovascular System , 2007, Circulation.

[13]  G. Bakris,et al.  Hypertension awareness, treatment, and control in chronic kidney disease. , 2008, The American journal of medicine.

[14]  V. Somers,et al.  Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure , 2007, Journal of hypertension.

[15]  Alexander G Logan,et al.  Relationship Between Overnight Rostral Fluid Shift and Obstructive Sleep Apnea in Drug-Resistant Hypertension , 2010, Hypertension.

[16]  L. Rump,et al.  [Pathophysiology of hypertension: what's new?]. , 2006, Herz.

[17]  Guido Grassi,et al.  Sympathetic nervous system: role in hypertension and in chronic kidney disease , 2012, Current opinion in nephrology and hypertension.

[18]  K. Rahn,et al.  Sympathetic Nerve Activity in End-Stage Renal Disease , 2002, Circulation.

[19]  R. Minutolo,et al.  Resistant Hypertension in Nondialysis Chronic Kidney Disease , 2013, International journal of hypertension.

[20]  R. Schmieder,et al.  Tonic Postganglionic Sympathetic Inhibition Induced by Afferent Renal Nerves? , 2012, Hypertension.

[21]  Giuseppe Mancia,et al.  Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure , 2011, Hypertension.

[22]  C. Bergamaschi,et al.  Rostral ventrolateral medulla : A source of sympathetic activation in rats subjected to long-term treatment with L-NAME. , 1999, Hypertension.

[23]  Dominik Linz,et al.  Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2012, Hypertension.

[24]  G. Mancia,et al.  Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[25]  Symplicity Htn Investigators,et al.  Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.

[26]  V. Campese,et al.  Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. , 2002, American journal of hypertension.

[27]  Xiaoqiang Yao,et al.  Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. , 2005, The Journal of clinical investigation.

[28]  E. Ritz,et al.  Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockers , 2001 .

[29]  V. Campese,et al.  Renal afferent denervation prevents hypertension in rats with chronic renal failure. , 1995, Hypertension.

[30]  S. Genovesi,et al.  Renal chemoreceptors. , 1981, Journal of the autonomic nervous system.

[31]  V. Campese,et al.  Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. , 1997, Kidney international.

[32]  G. Desir,et al.  Catecholamines Regulate the Activity, Secretion, and Synthesis of Renalase , 2008, Circulation.

[33]  김희진,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis , 2012 .

[34]  H. Seller,et al.  Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs. , 1997, Circulation research.

[35]  S. Achenbach,et al.  Renal sympathetic denervation does not aggravate functional or structural renal damage. , 2013, Journal of the American College of Cardiology.

[36]  P. Blankestijn,et al.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. , 1999, The New England journal of medicine.

[37]  F. Mahfoud [Renal denervation in hypertension - pro]. , 2012, Deutsche medizinische Wochenschrift.

[38]  M. Koss,et al.  A limited renal injury may cause a permanent form of neurogenic hypertension. , 1998, American journal of hypertension.

[39]  P. Blankestijn,et al.  Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. , 2002, Journal of the American College of Cardiology.

[40]  G. Beck,et al.  β-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  R. Converse,et al.  Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.

[42]  H. Krum,et al.  Sympatho-renal axis in chronic disease , 2011, Clinical Research in Cardiology.

[43]  S. Schreiber,et al.  Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. , 1993, Circulation research.

[44]  P. Golino,et al.  Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. , 2003, Journal of the American College of Cardiology.

[45]  V. Oberhauser,et al.  Moxonidine treatment of hypertensive patients with advanced renal failure , 2003, Journal of hypertension.

[46]  M. Woodward,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.

[47]  J. Stegbauer,et al.  Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. , 2005, Cardiovascular research.

[48]  V. Campese Neurogenic factors and hypertension in chronic renal failure. , 1997, Journal of nephrology.

[49]  E. Herzog,et al.  Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Meta- , 2013 .

[50]  M. Ishii,et al.  Elevated plasma catecholamines in hypertensives with primary glomerular diseases. , 1983, Hypertension.

[51]  C. Zoccali,et al.  Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. , 2002, Kidney international.

[52]  E. Ritz,et al.  Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. , 2001, Kidney international.

[53]  M. Uder,et al.  Renal Denervation in a Hypertensive Patient With End‐Stage Renal Disease and Small Arteries: A Direction for Future Research , 2012, Journal of clinical hypertension.

[54]  W. J. Elliott,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2010 .

[55]  W. Fang,et al.  Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. , 2010, European journal of internal medicine.

[56]  G. Dibona Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[57]  V. Campese,et al.  Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. , 2004, American journal of physiology. Heart and circulatory physiology.

[58]  D. Morgan,et al.  L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[59]  B. Conrad,et al.  Relationship Between Circadian Blood Pressure Patterns and Progression of Early Carotid Atherosclerosis: A 3-Year Follow-Up Study , 2000, Circulation.

[60]  R. Katholi,et al.  Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. , 1984, Journal of hypertension.

[61]  D. Marcelli,et al.  Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. , 2010, Journal of the American College of Cardiology.

[62]  R. Victor,et al.  A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. , 1999, Hypertension.

[63]  G. Dibona Neural control of the kidney: past, present, and future. , 2003, Hypertension.

[64]  P. Blankestijn,et al.  Atorvastatin reduces sympathetic activity in patients with chronic kidney disease , 2011, Journal of hypertension.

[65]  M. Uder,et al.  Vascular and renal hemodynamic changes after renal denervation. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[66]  P. Blankestijn,et al.  Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[67]  S. Carlson,et al.  Neurohormonal regulation of the sympathetic nervous system: New insights into central mechanisms of action , 2008, Current hypertension reports.

[68]  G. Bakris,et al.  Beta blockers in the management of chronic kidney disease. , 2006, Kidney international.

[69]  P. Blankestijn,et al.  Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis , 2007, Journal of hypertension.

[70]  W. Weichert,et al.  Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. , 2007, The American journal of pathology.

[71]  H. Krum,et al.  Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. , 2013, International journal of cardiology.

[72]  Carmine Zoccali,et al.  Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease , 2008, Current opinion in nephrology and hypertension.

[73]  L. Rump,et al.  [Pathophysiology of hypertension: what's new?]. , 2006, Herz.